Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070380
Filing Date
2025-05-13
Accepted
2025-05-13 16:15:33
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20250331.htm   iXBRL 10-Q 2266054
2 EX-10.5 spro-ex10_5.htm EX-10.5 137360
3 EX-10.10 spro-ex10_10.htm EX-10.10 142732
4 EX-31.1 spro-ex31_1.htm EX-31.1 11958
5 EX-32 spro-ex32.htm EX-32 6798
6 GRAPHIC img178000270_0.jpg GRAPHIC 46934
  Complete submission text file 0000950170-25-070380.txt   8862179

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spro-20250331.xsd EX-101.SCH 1363543
69 EXTRACTED XBRL INSTANCE DOCUMENT spro-20250331_htm.xml XML 1174077
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 25940324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)